Therapeutic Hotline: Letter
Efficacy and safety of vismodegib in patients with basal cell carcinoma: An Italian Center experience
Massimiliano Scalvenzi,
Massimiliano Scalvenzi
Department of Dermatology, University of Naples Federico II, Naples, Italy
Search for more papers by this author Alessia Villani,
Corresponding Author
Alessia Villani
Department of Dermatology, University of Naples Federico II, Naples, Italy
Correspondence
Alessia Villani, Department of Dermatology, University of Naples Federico II, Naples, Italy, Via Pansini 5, 80,131 Naples, Italy.
Email: [email protected]
Search for more papers by this author Claudia Costa,
Claudia Costa
Department of Dermatology, University of Naples Federico II, Naples, Italy
Search for more papers by this author Milena Cappello,
Milena Cappello
Department of Dermatology, University of Naples Federico II, Naples, Italy
Search for more papers by this author
Massimiliano Scalvenzi,
Massimiliano Scalvenzi
Department of Dermatology, University of Naples Federico II, Naples, Italy
Search for more papers by this author Alessia Villani,
Corresponding Author
Alessia Villani
Department of Dermatology, University of Naples Federico II, Naples, Italy
Correspondence
Alessia Villani, Department of Dermatology, University of Naples Federico II, Naples, Italy, Via Pansini 5, 80,131 Naples, Italy.
Email: [email protected]
Search for more papers by this author Claudia Costa,
Claudia Costa
Department of Dermatology, University of Naples Federico II, Naples, Italy
Search for more papers by this author Milena Cappello,
Milena Cappello
Department of Dermatology, University of Naples Federico II, Naples, Italy
Search for more papers by this author
First published: 24 May 2019
No abstract is available for this article.
REFERENCES
- Bánvölgyi, A. (2019). Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: A retrospective analysis of efficacy and side effects. Journal of Dermatological Treatment, 1, 1–1, 12. http://doi.org/10.1080/09546634.2019.1601155. [Epub ahead of print].
- Flohil, S. C. (2013). Trends in basal cell carcinoma incidence rates: A 37-year Dutch observational study. The Journal of Investigative Dermatology, 133, 913–918.
- Lacouture, M. E. (2016). Characterization and management of Hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Ncologist, 2, 1218–1229.
- Russo, F. (2018). Neglected skin carcinomas and vismodegib: Our experience. Giornale italiano di dermatologia e venereologia. https://doi.org/10.23736/S0392-0488.18.05873-X. [Epub ahead of print].
- Scalvenzi, M. (2018). Vismodegib treatment in a HIV positive patient on antiretroviral therapy. Indian Journal of Dermatology, Venereology and Leprology, 84, 758–760.
- Sekulic, A. (2012). Efficacy and safety of vismodegib in advanced basal-cell carcinoma. The New England Journal of Medicine, 366, 2171–2179.
- Sekulic, A. (2017). Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study. BMC Cancer, 17, 332.
- U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute. (2009). Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. (v4.03: June 14, 2010).
